Stephane Hunot

List of Publications by Year in Descending Order

56 papers	13,093 citations	38 h-index	61 g-index
61 ext. papers	14,855 ext. citations	9.4 avg, IF	6.04 L-index

#	Paper	IF	Citations
56	Modelling α-Synuclein Aggregation and Neurodegeneration with Fibril Seeds in Primary Cultures of Mouse Dopaminergic Neurons. *Cells*, **2022**, 11, 1640	7.9	2
55	Glucocorticoid receptor in astrocytes regulates midbrain dopamine neurodegeneration through connexin hemichannel activity. *Cell Death and Differentiation*, **2019**, 26, 580-596	12.7	29
54	Effect of Vitamin D in HN9.10e Embryonic Hippocampal Cells and in Hippocampus from MPTP-Induced Parkinson's Disease Mouse Model. *Frontiers in Cellular Neuroscience*, **2018**, 12, 31	6.1	7
53	Neutral Sphingomyelinase Behaviour in Hippocampus Neuroinflammation of MPTP-Induced Mouse Model of Parkinson's Disease and in Embryonic Hippocampal Cells. *Mediators of Inflammation*, **2017**, 2017, 2470950	4.3	10
52	Analysis of monocyte infiltration in MPTP mice reveals that microglial CX3CR1 protects against neurotoxic over-induction of monocyte-attracting CCL2 by astrocytes. *Journal of Neuroinflammation*, **2017**, 14, 60	10.1	37
51	Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. *Brain*, **2017**, 140, 184-200	11.2	112
50	Strain 130b Evades Macrophage Cell Death Independent of the Effector SidF in the Absence of Flagellin. *Frontiers in Cellular and Infection Microbiology*, **2017**, 7, 35	5.9	13
49	Adaptive preconditioning in neurological diseases - therapeutic insights from proteostatic perturbations. *Brain Research*, **2016**, 1648, 603-616	3.7	39
48	e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease. *Mediators of Inflammation*, **2016**, 2016, 3937057	4.3	7
47	Understanding Dopaminergic Cell Death Pathways in Parkinson Disease. *Neuron*, **2016**, 90, 675-91	13.9	307
46	Neuroinflammation in Alzheimer's disease. *Lancet Neurology, The*, **2015**, 14, 388-405	24.1	2760
45	Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. *Lancet Neurology, The*, **2015**, 14, 855-866	24.1	286
44	A viral peptide that targets mitochondria protects against neuronal degeneration in models of Parkinson's disease. *Nature Communications*, **2014**, 5, 5181	17.4	30
43	Heat shock protein 60: an endogenous inducer of dopaminergic cell death in Parkinson disease. *Journal of Neuroinflammation*, **2014**, 11, 86	10.1	30
42	DAP12 and CD11b contribute to the microglial-induced death of dopaminergic neurons in vitro but not in vivo in the MPTP mouse model of Parkinson's disease. *Journal of Neuroinflammation*, **2013**, 10, 82	10.1	9
41	MFGE8 does not orchestrate clearance of apoptotic neurons in a mouse model of Parkinson's disease. *Neurobiology of Disease*, **2013**, 51, 192-201	7.5	7
40	Effects of oral administration of rotenone on gastrointestinal functions in mice. *Neurogastroenterology and Motility*, **2013**, 25, e183-93	4	51

39	Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. *Scientific Reports*, **2013**, 3, 1393	4.9	107
38	Neuroinflammation in Parkinson's disease. *Parkinsonism and Related Disorders*, **2012**, 18 Suppl 1, S210-2	3.6	411
37	Tumor necrosis factor-like weak inducer of apoptosis induces astrocyte proliferation through the activation of transforming-growth factor-α/epidermal growth factor receptor signaling pathway. *Molecular Pharmacology*, **2012**, 82, 948-57	4.3	15
36	Inflammation and Parkinson's disease. *Parkinson's Disease*, **2011**, 2011, 729054	2.6	8
35	Neurochemokines: a menage a trois providing new insights on the functions of chemokines in the central nervous system. *Journal of Neurochemistry*, **2011**, 118, 680-94	6	102
34	Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 6632-7	11.5	159
33	Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. *Journal of Clinical Investigation*, **2010**, 120, 2745-54	15.9	301
32	Neuroinflammation in Parkinson's disease: a target for neuroprotection?. *Lancet Neurology, The*, **2009**, 8, 382-97	24.1	1326
31	Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. *Journal of Clinical Investigation*, **2009**, 119, 182-92	15.9	668
30	Pleiotrophin receptor RPTP-zeta/beta expression is up-regulated by L-DOPA in striatal medium spiny neurons of parkinsonian rats. *Journal of Neurochemistry*, **2008**, 107, 443-52	6	19
29	Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid. *Journal of Neurochemistry*, **2008**, 107, 701-11	6	61
28	Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 18578-83	11.5	314
27	The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 3585-90	11.5	217
26	Neuroinflammatory processes in Parkinson's disease. *Parkinsonism and Related Disorders*, **2005**, 11 Suppl 1, S9-S15	3.6	154
25	JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 665-70	11.5	350
24	The role of glial reaction and inflammation in Parkinson's disease. *Annals of the New York Academy of Sciences*, **2003**, 991, 214-28	6.5	344
23	Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 5473-8	11.5	545
22	Neuroinflammatory processes in Parkinson's disease. *Annals of Neurology*, **2003**, 53 Suppl 3, S49-58; discussion S58-60	9.4	298

21	Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter. *Experimental Neurology*, **2003**, 184, 561-4	5.7	47
20	Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. *Journal of Neurochemistry*, **2002** , 83, 320-30	6	92
19	Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP. *Experimental Neurology*, **2002**, 177, 183-92	5.7	70
18	Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. *Journal of Neuroscience*, **2001**, 21, 2247-55	6.6	222
17	The inflammatory response in the Parkinson brain. *Clinical Neuroscience Research*, **2001**, 1, 434-443		33
16	Apoptosis. Death of a monopoly?. *Science*, **2001**, 292, 865-6	33.3	49
15	Deficiency in caspase-9 or caspase-3 induces compensatory caspase activation. *Nature Medicine*, **2000**, 6, 1241-7	50.5	282
14	Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 2875-80	11.5	586
13	Nitric oxide, glial cells and neuronal degeneration in parkinsonism. *Trends in Pharmacological Sciences*, **2000**, 21, 163-5	13.2	49
12	Caspase knockouts: matters of life and death. *Cell Death and Differentiation*, **1999**, 6, 1043-53	12.7	240
11	Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. *Movement Disorders*, **1999**, 14, 383-5	7	127
10	An immunohistochemical study of the distribution of brain-derived neurotrophic factor in the adult human brain, with particular reference to Alzheimer's disease. *Neuroscience*, **1999**, 88, 1015-32	3.9	145
9	FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. *Journal of Neuroscience*, **1999**, 19, 3440-7	6.6	369
8	Glial cell participation in the degeneration of dopaminergic neurons in Parkinson's disease. *Advances in Neurology*, **1999**, 80, 9-18		29
7	CD95 (APO-1/Fas) and Parkinson's disease. *Annals of Neurology*, **1998**, 44, 425-6	9.4	4
6	Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?. *Annals of Neurology*, **1998**, 44, S115-20	9.4	259
5	Nuclear translocation of NF-kappaB in cholinergic neurons of patients with Alzheimer's disease. *NeuroReport*, **1997**, 8, 2849-52	1.7	138
4	Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 7531-6	11.5	594

3	Trk neurotrophin receptors in cholinergic neurons of patients with AlzheimerÕs disease. *Dementia and Geriatric Cognitive Disorders*, **1997**, 8, 1-8	2.6	31
2	Nitric oxide synthase and neuronal vulnerability in ParkinsonÕs disease. *Neuroscience*, **1996**, 72, 355-63	3.9	485
1	Glial cell line-derived neurotrophic factor (GDNF) gene expression in the human brain: a post mortem in situ hybridization study with special reference to ParkinsonÕs disease. *Journal of Neural Transmission*, **1996**, 103, 1043-52	4.3	76